Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, Mukohara T, Lisberg A, Shimizu T, Spira AI, Tsurutani J, Damodaran S, Papadopoulos KP, Greenberg J, Kobayashi F, Zebger-Gong H, Wong R, Kawasaki Y, Nakamura T, Meric-Bernstam F.
Bardia A, et al. Among authors: kobayashi f.
J Clin Oncol. 2024 Apr 23:JCO2301909. doi: 10.1200/JCO.23.01909. Online ahead of print.
J Clin Oncol. 2024.
PMID: 38652877